Search
Phenylacetic acid
go.drugbank.com/drugs/DB09269ApprovedBecause it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China. … Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor.
Human varicella-zoster immune globulin
go.drugbank.com/drugs/DB11621ApprovedInvestigationalIt is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the disease severity in high-risk patients who
Cinnarizine
go.drugbank.com/drugs/DB00568ApprovedInvestigationalFirst synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness. … Combination use of cinnarizine with other nootropics, such as [piracetam] resulted in enhanced effect of boosting brain oxygen supply.
Products: CN - 25Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigational[L40026] It received subsequent approval for the same indications in Canada in May 2022. … [L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026]
Suprofen
go.drugbank.com/drugs/DB00870ApprovedWithdrawnAn ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigational[A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323] … Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease.
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc.
Etravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalIn 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development … On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg.
Uridine triacetate
go.drugbank.com/drugs/DB09144ApprovedWhen administered as the prodrug uridine triacetate, uridine can be used by essentially all cells to make uridine nucleotides, which compensates for the genetic deficiency in synthesis in patients with … Furthermore, orotic acid crystals in the urine can cause episodes of obstructive uropathy.
Ecabet
go.drugbank.com/drugs/DB05265InvestigationalEcabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis.
Categories: Compounds used in a research, industrial, or household setting